Call Time : 10:30 AM EST
Wall Street Time .
Slingshot members are talking to an expert! The topic is:
Reviewing the Small Cell Lung Cancer Landscape in Light of Recent Data, with a Focus on Lurbinectedin's Phase 3 Program
Ticker(s): PHM.MC, PHMMFWho's the expert?
Name: Dr Jack West - MD
Institution: Swedish Cancer Institute
- Medical oncologist (specialty in lung cancer) and Medical Director of the Thoracic Oncology Program at the Swedish Cancer Institute.
- Leads a wide range of clinical trials and has been actively involved with the SWOG Lung Cancer Committee as a Study Coordinator/Principal Investigator.
- Has published numerous articles in peer-reviewed literature, authored several book chapters, and serves as the Web Editor of JAMA Oncology and is on the editorial boards of Journal of Clinical Oncology, Journal of Medicine, Clinical Lung Cancer, and Journal of Thoracic Disease.
SPONSORED BY: PharmaMar
PharmaMar is a company focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor activity. We are an integrated company that seeks innovative products to provide healthcare professionals with new tools to treat cancer.
PharmaMar’s commitment to patients and to research has made it a world leader in the discovery of antitumor drugs of marine origin.
PharmaMar’s commitment to patients and to research has made it a world leader in the discovery of antitumor drugs of marine origin.
Interview Questions
Q1.
There has been some movement in therapeutic approvals in SCLC recently. Can you walk me through how you are currently treating a new SCLC patient who comes to you?
Added By: j_adminQ2.
How has Atezolizumab's inclusion in the NCCN guidelines for first line and maintenance changed your treatment approach?
- How important is FDA approval vs. guideline inclusion?
Q3.
How do you use and view nivolumab after FDA approval in light of the Checkmate 331 results?
Added By: j_admin